Skip to main content

Clinical Trials Using Poly ICLC

Review the clinical trials studying poly iclc on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: 28 locations
In Situ Immunomodulation for Unresectable and Metastatic Solid Tumors
Status: Active
Location: 2 locations
Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery
Status: Active
Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Poly-ICLC Vaccine for the Treatment of Prostate Cancer in Patients on Active Surveillance
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Vaccine for the Treatment of Patients with Advanced ALK Rearrangement Positive Non-Small Cell Lung Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
A Vaccine (PGV001) in Combination with Immunotherapy (CDX-301 and Poly-ICLC) for the Treatment of Prostate Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Personalized Cancer Vaccine for the Treatment of Muscle-invasive Bladder Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Peptide Vaccine (mBTCvax) Plus Durvalumab and Tremelimumab for the Treatment of Biliary Tract Cancers
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Mutant-CALR Peptide Vaccine for the Treatment of Patients with CALR Mutation Positive Myeloproliferative Neoplasms
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Pooled Mutant KRAS-Targeted Long Peptide Vaccine in Combination with Nivolumab and Ipilimumab for the Treatment of Locally Advanced, Unresectable or Metastatic KRAS Mutated Non-small Cell Lung Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Focused Ultrasound Ablation and Intratumoral PolyICLC for the Treatment of Patients with Advanced Resectable Melanoma Receiving Immunotherapy before Surgery
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Mutant KRAS-Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland